Drug intelligence / Profile preview

elixcyte

Development stage: Phase 3
Lead developer: UnicoCell Biomed
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intraarticular, Intravenous

Overview

ELIXCYTE is an allogeneic, expanded adipose-derived stem cell (ADSC) therapy developed by UnicoCell Biomed. It is composed of mesenchymal stem cells harvested from adipose tissue, which are then expanded in vitro. The therapy is designed to treat degenerative and inflammatory diseases by promoting tissue repair and modulating the immune response through paracrine signaling. ELIXCYTE is currently in Phase III clinical trials for knee osteoarthritis, where it is administered via intra-articular injection to reduce pain and improve joint function. It is also being investigated in Phase I/II trials for moderate to severe chronic kidney disease and spinal cord injury.

Brand names: ELIXCYTE
Other names: Adipose-Derived Stem CellsADSCsallogeneic adipose-derived stem cells

Beyond the preview

Go deeper on elixcyte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on elixcyte.

Explore the full profile